Equities research analysts at HC Wainwright began coverage on shares of Opexa Therapeutics (NASDAQ:ACER) in a report released on Wednesday, MarketBeat.com reports. The brokerage set a “buy” rating on the biopharmaceutical company’s stock.

Separately, ValuEngine upgraded Opexa Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, September 22nd.

Opexa Therapeutics (NASDAQ:ACER) traded up $0.70 during trading on Wednesday, hitting $13.50. The company had a trading volume of 51,372 shares, compared to its average volume of 31,480. The company has a market cap of $94.30, a P/E ratio of -2.35 and a beta of 2.26. Opexa Therapeutics has a 1-year low of $5.69 and a 1-year high of $22.63.

Opexa Therapeutics (NASDAQ:ACER) last posted its earnings results on Monday, November 13th. The biopharmaceutical company reported ($1.09) EPS for the quarter.

ILLEGAL ACTIVITY WARNING: “HC Wainwright Begins Coverage on Opexa Therapeutics (ACER)” was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://theolympiareport.com/2017/12/20/opexa-therapeutics-acer-coverage-initiated-by-analysts-at-hc-wainwright.html.

About Opexa Therapeutics

Acer Therapeutics Inc, formerly Opexa Therapeutics, Inc, is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001.

Receive News & Ratings for Opexa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opexa Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.